|
|
|
Insider
Information: |
Schiff Dr Drew |
Relationship: |
Managing Member |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
6,105,958 |
|
Indirect Shares
|
5,157,820 |
|
|
Direct
Value |
$11,161,992 |
|
|
Indirect Value
|
$1,188,745 |
|
|
Total
Shares |
11,263,778 |
|
|
Total
Value |
$12,350,737 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
Percentage
Gain/Loss : |
-80.9%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Interpharm HoldingsInc |
IPAH |
|
2007-11-08 |
548,315 |
|
0 |
Premium* |
|
Aravive Inc |
ARAV |
10% Owner |
2014-03-26 |
0 |
2015-01-27 |
2,139,568 |
Premium* |
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2014-05-23 |
0 |
2016-06-02 |
2,583,797 |
Premium* |
|
Zeltiq Aesthetics Inc |
ZLTQ |
Director, 10% Owner |
2017-04-28 |
0 |
2017-04-28 |
0 |
Premium* |
|
Aclaris Therapeutics, Inc. |
ACRS |
Director |
2023-06-02 |
4,507 |
2023-06-02 |
434,455 |
Premium* |
|
Zosano Pharma Corp |
ZSAN |
10% Owner |
2019-12-02 |
2,718,226 |
2019-04-11 |
0 |
Premium* |
|
Elevation Oncology, Inc. |
ELEV |
Managing Member |
2021-06-29 |
2,834,910 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2023-06-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,507 |
4,507 |
0 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-11-14 |
4 |
AS |
$17.08 |
$23,417 |
I/I |
(1,371) |
434,455 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-11-11 |
4 |
AS |
$17.06 |
$702,177 |
I/I |
(41,160) |
435,826 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-11-10 |
4 |
AS |
$17.02 |
$193,995 |
I/I |
(11,395) |
476,986 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-26 |
4 |
AS |
$17.01 |
$247,253 |
I/I |
(14,540) |
488,381 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-25 |
4 |
AS |
$17.02 |
$204,516 |
I/I |
(12,018) |
502,921 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-24 |
4 |
AS |
$17.01 |
$248,586 |
I/I |
(14,616) |
514,939 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-18 |
4 |
AS |
$16.89 |
$542,022 |
I/I |
(32,093) |
529,555 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-17 |
4 |
AS |
$16.05 |
$320,087 |
I/I |
(19,944) |
561,648 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-07 |
4 |
AS |
$16.16 |
$118,349 |
I/I |
(7,324) |
581,592 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-06 |
4 |
AS |
$16.54 |
$625,744 |
I/I |
(37,839) |
588,916 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-10-04 |
4 |
AS |
$16.01 |
$123,259 |
I/I |
(7,700) |
626,755 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-06-17 |
4 |
AS |
$15.14 |
$296,269 |
D/D |
(19,565) |
0 |
0 |
% |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2022-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,356 |
19,565 |
0 |
- |
|
ELEV |
Elevation Oncology, Inc. |
Managing Member |
|
2021-06-29 |
4 |
B |
$16.00 |
$3,000,000 |
D/D |
187,500 |
2,834,910 |
2.44 |
% |
|
ELEV |
Elevation Oncology, Inc. |
Managing Member |
|
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,351,592 |
2,647,410 |
0 |
- |
|
ELEV |
Elevation Oncology, Inc. |
|
|
2021-06-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
295,818 |
|
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2020-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,333 |
16,209 |
0 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2020-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,876 |
8,876 |
0 |
- |
|
ZSAN |
Zosano Pharma Corp |
10% Owner |
|
2019-12-02 |
4 |
A |
$1.45 |
$1,000,000 |
D/D |
689,655 |
2,718,226 |
0 |
- |
|
ZSAN |
Zosano Pharma Corp |
10% Owner |
|
2019-04-11 |
4 |
A |
$3.50 |
$1,499,999 |
D/D |
428,571 |
2,028,571 |
0 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2017-08-16 |
4 |
B |
$23.02 |
$2,499,995 |
I/I |
108,601 |
634,455 |
2.1 |
- |
|
ACRS |
Aclaris Therapeutics, Inc... |
Director |
|
2017-08-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
525,854 |
|
- |
|
ZLTQ |
Zeltiq Aesthetics Inc |
Director |
|
2017-04-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,597,742) |
0 |
0 |
- |
|
ZLTQ |
Zeltiq Aesthetics Inc |
Director |
|
2017-04-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,137) |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|